Thanking viewers of my presentation slides on topics such as Biopharmaceutics Classification System, BCS, FDA, PAT, QbD, Biosimilars, Product Development, Process Development, Data Integrity, Human Factors, and GMPs, biowaivers, warning letters

1. Slideshare Analytics
Ajaz S. Hussain, Ph.D.
1 March 2014
3/1/2014
A2ZPharmSci@msn.com
1

2. Viewers of my uploads on Slideshare®
Top 10
Viewers from 122 Countries
%
16.1
Portugal
6.5
United Kingdom
3.6
Ukraine
3.1
Canada
2.4
Switzerland
2.0
Japan
1.7
Germany
1.7
France
A2ZPharmSci@msn.com
36.2
India
3/1/2014
United States
1.6
2

3. Top content (21-27 February 2014)
Name
Views
Data in÷teg÷ri÷ty: Time to Integrate Human Factors
90
Human factors in GMP (7 February 2014)
61
Biopharmaceutics Classification System (BCS) & Waiver of
Bioequivalence
51
Nanotechnology Regualtory Perspectives, Challenges & Issues
13 February 2014 Post
47
US FDA's PAT Guidance – 10 years and now
17
3/1/2014
A2ZPharmSci@msn.com
3

4. Top content: Past six months
Name
Views
Biopharmaceutics Classification System (BCS) & Waiver of
Bioequivalence
1,540
Data in÷teg÷ri÷ty: Time to Integrate Human Factors
588
Human factors in GMP (7 February 2014)
492
Pharmaceutical Product & Process Design & Quality
332
Pharmaceutical Quality by Design: Review of Progress and
Challenges
187
3/1/2014
A2ZPharmSci@msn.com
4

5. Top content: Past one year
Name
Views
Biopharmaceutics Classification System (BCS) & Waiver of
Bioequivalence
6,337
Development of Biosimilar Products: Determinants of Success
993
Chemometrics, Pharmacometrics and Econometrics
Dimensions_of_Quality
654
Regulatory Challenges: Lecture @ University of Michigan 21
Feb 2013
591
Data in÷teg÷ri÷ty: Time to Integrate Human Factors
588
3/1/2014
A2ZPharmSci@msn.com
5

6. Actions
•
•
•
•
•
•
FACEBOOK: 6
TWITTER: 9
FAVORITES: 14
EMAILS: 218
LINKEDIN: 374
TOTAL VIEWS: 16,517
3/1/2014
A2ZPharmSci@msn.com
6